MicroRNAs as therapeutic strategy for hepatitis B virus-associated hepatocellular carcinoma: Current status and future prospects

doi:10.3748/wjg.v20.i20.5973

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 20

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6363)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

384

WORD

253

HTML

3270

Figures (1-1)

205

Tables (1-2)

160

Sum=4272

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1212

Download

879

Sum=2091

May 28, 2014 (publication date) through Jul 23, 2024

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. May 28, 2014; 20(20): 5973-5986
Published online May 28, 2014. doi: 10.3748/wjg.v20.i20.5973

Table 2 Examples of miRNAs involved in chronic hepatitis B infection or hepatitis B virus-related hepatocellular carcinoma

miRNA	Target gene	Process(es) affected
miR-1	HDAC4	HBV replication
miR-1	E2F5	Cell proliferation; cell cycle
miR-199a-3p, miR-210	HBV genome	HBV replication and antigen production
miR-501	HBXIP	HBV replication
miR-141	PPARA	HBV replication
miR-29a	PTEN	Cell migration
miR-101	DNMT3A	DNA methylation and gene silencing
let-7	STAT3	Cell proliferation
miR-148a	HPIP	Cell proliferation; migration; EMT

Their validated miRNA targets and subsequent effects on cells are listed accordingly. HBV: Hepatitis B virus; EMT: Epithelial-mesenchymal transition.

Citation: Tan YLJ, Chen WN. MicroRNAs as therapeutic strategy for hepatitis B virus-associated hepatocellular carcinoma: Current status and future prospects. World J Gastroenterol 2014; 20(20): 5973-5986
URL: https://www.wjgnet.com/1007-9327/full/v20/i20/5973.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i20.5973